FDA approves Novo Nordisk's injection for obesity

By Natalie Grover (Reuters) - The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans. The injectable drug, to be marketed as Saxenda, is the second obesity treatment to be approved this year after Orexigen Therapeutics Inc's oral medication Contrave in September. Saxenda enters a market that is yet to realize its potential due to limited effectiveness of existing drugs, reimbursement hurdles, bungled launches and the perception of obesity as a 'lifestyle' disease. ...



via Health News Headlines - Yahoo News http://ift.tt/1sVvwvb